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conBACKGROUND Magnetic resonance imaging (MRI) of patients with conventional implantable cardioverter-
deﬁbrillators (ICD) is contraindicated.
OBJECTIVES This multicenter, randomized trial evaluated safety and efﬁcacy of a novel ICD system specially designed
for full-body MRI without restrictions on heart rate or pacing dependency. The primary safety objective was >90%
freedom from MRI-related events composite endpoint within 30 days post-MRI. The primary efﬁcacy endpoints were
ventricular pacing capture threshold and ventricular sensing amplitude.
METHODS Subjects received either a single- or dual-chamber ICD. In a 2:1 randomization, subjects either underwent
MRI at 1.5-T of the chest, cervical, and head regions to maximize radiofrequency exposure up to 2 W/kg speciﬁc
absorption rate and gradient ﬁeld exposure to 200 T/m/s per axis (MRI group, n ¼ 175), or they underwent a 1-h waiting
period without MRI (control group, n ¼ 88). A subset of MRI patients underwent ventricular ﬁbrillation induction testing
post-MRI to characterize deﬁbrillation function.
RESULTS In 42 centers, 275 patients were enrolled (76%male, age 60.4 13.8 years). The safety endpoint was met with
100% freedom from the composite endpoint (p < 0.0001). Both efﬁcacy endpoints were met with minimal differences in
the proportion of MRI and control patients who demonstrated a #0.5 V increase in ventricular pacing capture threshold
(100% MRI vs. 98.8% control, noninferiority p < 0.0001) or a #50% decrease in R-wave amplitude (99.3% MRI vs.
98.8% control, noninferiority p ¼ 0.0001). A total of 34 ventricular tachyarrhythmia/ventricular ﬁbrillation episodes (20
induced; 14 spontaneous) occurred in 24 subjects post-MRI, with no observed effect on sensing, detection, or treatment.
CONCLUSIONS This is the ﬁrst randomized clinical study of an ICD system designed for full-body MRI at 1.5-T. These
data support that the system is safe and the MRI scan does not adversely affect electrical performance or efﬁcacy.
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2582T he implantable cardioverter-deﬁbrillator(ICD) was approved in 1985 for theprevention of sudden cardiac death.
Subsequent multicenter studies demonstra-
ted the efﬁcacy of ICDs to reduce mortality
for both primary and secondary prevention
(1–3). Many advances have been made in
this therapy over the past 30 years, including
the addition of pacing therapy and downsiz-
ing of the device, which allowed for pectoralimplantation and transvenous leads. Magnetic reso-
nance imaging (MRI), however, has remained contra-
indicated for ICD patients, because of the presumed
risks associated with such scans in this patient group
(4). For these reasons, there are presently no U.S.
Food and Drug Administration–approved MRI-safe
ICD systems, even though MRI has been performed
safely in certain circumstances. The lack of MRI ac-
cess to device patients has become a growing issue,
as MRI usage as a diagnostic tool has evolved to
become the preferred imaging modality in many clin-
ical situations (5–7). It is now estimated that more
than one-half of ICD patients will need MRI over a
10-year period (8).SEE PAGE 2589Over the past several years, a few pacemaker
systems have been modiﬁed to allow for safe MRI
(9–11). The issues required for safe MRI for ICDs are
more complex, because in addition to pacing func-
tionality, the risk of inducing or undersensing ven-
tricular arrhythmias may be increased. Therefore,
accurately sensing ventricular ﬁbrillation and suc-
cessful deﬁbrillation are required. A comprehensive
pre-clinical series of experiments showed the safety
of such a system in animal studies, bench testing,
and computer simulation (12). The present study
represents the ﬁrst human randomized study of
an MRI-safe ICD system designed for full-body
imaging.
METHODS
TRIAL DESIGN AND OVERSIGHT. This multicenter,
international, parallel-group, randomized trial eval-
uated the safety and efﬁcacy of patients who received
a novel ICD system and who were subjected to an MRId research grants from Toshiba Medical Systems. Prof. Merke
to Medtronic and Boston Scientiﬁc. Ms. Landborg and Mr. Cer
to Medtronic, Boston Scientiﬁc, and St. Jude Medical. All other au
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received April 6, 2015; revised manuscript received April 24, 201examination. All participants met Class I or II indi-
cation for receiving a de novo ICD, with no re-
strictions on pacemaker dependence. All subjects
provided written informed consent. The trial was
sponsored by the manufacturer, Medtronic, Inc.
(Minneapolis, Minnesota). The Declaration of Hel-
sinki was followed, as well as laws and regulations
of participating countries. The ethics committee at
each participating institution approved the protocol.
Trained center personnel collected the data, and data
integrity was maintained via programmatic edit
checks and source data veriﬁcation by the sponsor.
STUDY DEVICE. Consenting patients received pec-
toral implantation of an Evera MRI ICD (MR-ICD,
Medtronic) connected to commercially-available
deﬁbrillator leads (model 6935M or 6947M [Med-
tronic], 55- and 62-cm lead lengths). Per physician
discretion, patients received a single- or dual-chamber
ICD. For the dual-chamber ICD, a commercially-
available pacing lead (model 5076, Medtronic) that
has been demonstrated to be safe for MRI scanning (13)
was used.
The MR-ICD had speciﬁc design and material
modiﬁcations to reduce interaction with the MRI
environment that have been described elsewhere
(12). Brieﬂy, ferromagnetic material was reduced, a
hall sensor replaced the mechanical reed switch, ﬁl-
ters to prevent gradient and radiofrequency (RF)
energy coupling were added, and battery circuitry
protection was added. Additionally, a programmable
SureScan mode was included to provide asynchro-
nous or disabled pacing and to disable tachyar-
rhythmia detection during the MRI scanning
procedure. SureScan mode is designed to be pre-
served during a full electrical reset, and it times out
after 6 h to mitigate the risk of therapies being
inadvertently left disabled after scanning is
completed. The system was designed and tested to
be MRI-conditional when utilizing this device with
speciﬁc SureScan lead models and lengths in a 1.5-T
MRI environment.
RANDOMIZATION. After successful MR-ICD implan-
tation, patients were randomly assigned 2:1 to un-
dergo MRI (MRI group) or to undergo a 1-h waiting
period without MRI (control group) 9 to 12 weeks after
implant. Randomization assignments were centrallyly is a paid speaker for Medtronic. Dr. Ciuffo is a
kvenik are employees of Medtronic. Dr. Kanal is a
thors have reported that they have no relationships
ntin Fuster.
5, accepted April 27, 2015.
TABLE 1 MRI Examination Sequences for Study Scan
Body Region Sequence Name
Cardiac SSFP cine, short-axis, 10 slices
SSFP cine, short-axis, 3 slices
Delayed enhancement inversion recovery, short-axis, 10 slices
No contrast media given
K-space segmented fast gradient echo cine, short-axis, 3 slices
SSFP cine, horizontal long-axis, 1 slice
SSFP cine vertical long-axis, 1 slice
K-space segmented fast gradient echo cine,
horizontal long-axis, 1 slice
Thoracic spine T2 fast spin echo, sagittal plane
Cervical spine T2 fast spin echo, sagittal plane
Head Diffusion-weighted imaging, transverse plane
MRI ¼ magnetic resonance imaging; SSFP ¼ steady state free precession.
FIGURE 1 Image Quality Scan Sequences
Representative cardiac images from a study patient implanted with an Evera MRI system
(Medtronic, Inc., Minneapolis, Minnesota). Horizontal long-axis (A) and short-axis (B) cine
k-space segmented fast gradient echo acquisitions.
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blocked groups.
Subjects were evaluated post-implant at 2 months,
at 9 to 12 weeks for MRI/waiting visit, and then at
1-week and 1-month post-MRI/waiting, 6 months
post-implant, and every 6 months thereafter. Routine
device measurements were collected, including pac-
ing capture threshold, sensing amplitudes, and
impedance values for each lead.
MRI SCAN. MRI scans were performed with 1.5-T
systems from any of the 4 most common MRI manu-
facturers: Siemens (Berlin, Germany), Philips (Eind-
hoven, the Netherlands), GE Healthcare (Little
Chalfont, United Kingdom), and Toshiba (Tokyo,
Japan). To test the safety of MRI comprehensively
and to include clinically-relevant evaluations, 10 MRI
head, cervical spine, and chest scan sequences were
performed (Table 1). The scan protocol included MRI
scans with maximized RF energy deposition up to
speciﬁc absorption rate levels of 2 W/kg body and
scans with maximized gradient slew rates (up to
200 T/m/s per axis). The body coil served as the RF
transmit coil in all cases. Static magnetic ﬁeld expo-
sure was approximately 50 min, with cumulative
active MRI scan times of approximately 20 min
(gradient and RF ﬁeld exposure). Pulse oximetry,
electrocardiography, and verbal communication pro-
vided monitoring. An external deﬁbrillator was
required to be immediately available during the scan,
and qualiﬁed personnel were required to be present
to manage any potential emergency situation.
The assessment of image quality was an ancillary
objective of the study, and only some cardiac se-
quences in the protocol, such as k-space segmented
fast gradient echo cine acquisitions, were chosen for
this assessment. Representative examples of cardiac
imaging are shown in Figure 1 and theOnlineAppendix.
POST-MRI INDUCTION TESTING. Because deﬁbrilla-
tion is a primary function of ICDs, a subset of patients
in the MRI group consented to undergo induction
testing post-MRI to characterize ventricular ar-
rhythmia sensing and detection as part of a pre-
planned substudy. In addition, subjects in the MRI
group were required to undergo induction testing at
the 1-month post-MRI visit for either of the following
conditions: 1) a >30% decrease in ventricular sensing
amplitude was observed compared with immediately
pre-MRI; or 2) ventricular sensing amplitude
measured <3 mV.
PRIMARY OBJECTIVES. The trial had 3 primary
objectives. The primary safety objective was to
demonstrate >90% freedom from MRI-related events.
The occurrence of any of the following was consideredan MRI-related event: 1) sustained ventricular tachy-
arrhythmia (ventricular tachycardia [VT]/ventricular
ﬁbrillation [VF]) during SureScan mode; 2) complica-
tion within 30 days and related to the MRI; or 3) loss of
capture within 30 days of MRI. All events were
reviewed by a clinical events committee. There were 2
primary efﬁcacy endpoints: ventricular pacing capture
threshold (VPCT) and ventricular sensing amplitude
changes from the MRI/waiting period to 1-month post-
MRI/waiting period. VPCT, measured at 0.4 ms in both
the MRI and control groups, was deﬁned as a failure if
it increased by >0.5 V. Sensing amplitude was
considered a failure if a >50% decrease in R-wave
amplitude (or >25% decrease if <3 mV) was noted.
VT/VF DETECTION ANCILLARY OBJECTIVE . All
device-detected VT and VF episodes (induced or
spontaneous) with stored electrogram available and
nonsustained VT/VF episodes of at least 16 beats
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2584were adjudicated by an episode review committee.
Episodes that were classiﬁed as polymorphic VT/VF,
and with at least 4 intervals $300 ms, with 1 interval
$600 ms, or with the pre-detection time lasting more
than 10 s, were further evaluated for VF under-
sensing and amount of detection delay. A clinically-
signiﬁcant detection delay was deﬁned as $5 s.
STATISTICAL ANALYSIS. All primary endpoints were
tested using a 1-sided test with an a-level of 0.025. For
the primary safety objective, a 1-proportion binomial
exact test was used. The Farrington-Manning test of
2 independent proportions was used to test the pri-
mary efﬁcacy endpoints. The noninferiority margins
were 10% (VPCT) and 8% (sensing). Mean change wasFIGURE 2 Primary Objectives Analysis Population
Patients en
(n = 27
Allocated to undergo MRI scan
(n = 175)
Exited prior to MRI visit
(n = 7)
Analyzed ventricular PCT (n = 154)
Excluded ventricular PCT (n = 1)
Analyzed ventricular sensing (n = 153)
Excluded ventricular sensing (n = 2)
Exited prior to one-month
post MRI visit
(n = 1)
Underwent MRI scan (n = 156)*
Did not undergo MRI scan (n = 12)
(n = 4) 
(n = 6) 
(n = 6) 
(n = 3) 
(n = 1) 
(n = 1) 
(n = 1) 
(n = 1) 
(n = 0) 
Increase >0.5V PCT prior to MRI  
Increase >0.5V PCT prior to MRI  
No intrinsic rhythm
Death
Missed visit
MRI scan not done
Patient withdrawal
Death
Patient withdrawal
Randomized P
(n = 2
This is a ﬂow chart of enrolled patients through the primary ventricular
scanned patients were included in the primary safety objective analysis.
withdrew (n ¼ 1). EGM ¼ electrocardiogram; ICD ¼ implantable cardiov
threshold; RV ¼ right ventricular; other abbreviations as in Figure 1.tested using paired Student t tests. Continuous vari-
ables are reported as mean  SD.
RESULTS
Patient enrollment began April 17, 2014, and
concluded September 11, 2014, with 275 patients
enrolled at 42 centers located in 13 countries within
North and South America, Europe, Asia, and the
Middle East. In the trial, 263 patients successfully
received an MR-ICD (Figure 2) and were randomized
to undergo MRI (n ¼ 175) or a waiting period without
MRI (n ¼ 88). Baseline characteristics are presented
in Table 2; this was a typical group of patients un-
dergoing ICD implantation. The mean follow-uprolled
5)
Analyzed ventricular PCT (n = 81)
Excluded ventricular PCT (n = 2)
Analyzed ventricular sensing (n = 82)
Excluded ventricular sensing (n = 1)
Exited prior to one-month
post waiting period visit
(n = 1)
Underwent waiting period (n = 84)
Did not undergo waiting period (n = 3)
Exited prior to waiting period
visit (n = 1)
Allocated to undergo waiting period
(n = 88)
Excluded (n = 12)
MR-ICD implant not attempted (n = 11) 
(n = 3) 
(n = 1) 
(n = 1) 
(n = 0) 
(n = 1) 
(n = 0) 
(n = 1) 
(n = 1) 
(n = 1) EGM strip missing
PCT >2.0V pre-waiting
RV lead revision
Non-study system implanted 
Missed visit
Death
Patient withdrawal
Death
Patient withdrawal
atients 2:1
63)
PCT and ventricular sensing endpoints. *A total of 147 of 156 MRI
Patients not included missed the 1-month post-MRI visit (n ¼ 8) or
erter-deﬁbrillator; MR ¼ magnetic resonance; PCT ¼ pacing capture
TABLE 2 Baseline Demographic and Clinical Characteristics
MRI
Group
(n ¼ 175)
Control
Group
(n ¼ 88)
Total
(n ¼ 263)
Age, yrs 60.5  13.5 60.1  14.3 60.4  13.8
Sex
Male 135 (77.1) 66 (75.0) 201 (76.4)
Female 40 (22.9) 22 (25.0) 62 (23.6)
NYHA functional class
I 15 (8.6) 14 (15.9) 29 (11.0)
II 93 (53.1) 43 (48.9) 136 (51.7)
III 23 (13.1) 12 (13.6) 35 (13.3)
IV 1 (0.6) 1 (1.1) 2 (0.8)
Subject does not have
heart failure
29 (16.6) 12 (13.6) 41 (15.6)
Classiﬁcation not available 14 (8.0) 6 (6.8) 20 (7.6)
ICD indication
Primary prevention 130 (74.3) 64 (72.7) 194 (73.8)
Secondary prevention 45 (25.7) 24 (27.3) 69 (26.2)
Atrial ﬁbrillation 48 (27.4) 18 (20.5) 66 (25.1)
ICD system conﬁguration
VR ICD (vs. DR ICD) 92 (52.6) 51 (58.0) 143 (54.4)
6935M (vs. 6947M) 119 (68.0) 60 (68.2) 179 (68.1)
Values are mean  SD or n (%).
DR ¼ dual chamber; ICD ¼ implantable cardioverter-deﬁbrillator; MRI ¼
magnetic resonance imaging; NYHA ¼ New York Heart Association; VR ¼ single
chamber.
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months.
SAFETY. Full-body MRI examinations were per-
formed in 156 patients representing the MRI group,
and 147 included in the safety objective analysis were
followed to 1-month post-MRI or longer. Patients not
included in the safety analysis either missed the
1-month post-MRI visit (n ¼ 8) or withdrew (n ¼ 1),
but they were all seen at the 1-week post-MRI visit.
None of these patients experienced an MRI-related
complication. The safety endpoint was met (100%
complication-free rate) with no sustained ventricular
tachyarrhythmia episodes during MRI, and no MRI-
related complications or loss of capture (p < 0.0001).
A total of 5 MRI-related observations occurred in
5 patients. No action was required for 2 patients who
reported implant site warmth and 1 who reported
back pain during scanning. One patient, reporting a
burning sensation in the forehead, received x-rays to
exclude the presence of a metallic foreign body. One
patient experienced atrial tachycardia at a rate of
150 beats/min during the scan, associated with asyn-
chronous pacing. The scan was stopped, and the pa-
tient’s rhythm was converted to normal rhythm using
atrial antitachycardia pacing noninvasively through
the MR-ICD. Scanning was continued and wascompleted uneventfully. The patient subsequently
experienced multiple other atrial tachycardia epi-
sodes during the follow-up period, so presumably
was predisposed to this arrhythmia.
Twelve patients died during the study, of which 4
were in the control group and 8 in the MRI group. In
the latter group, 5 of these subjects died before un-
dergoing MRI, 1 died 30 days post-MRI due to small
cell lung carcinoma, 1 died 109 days post-MRI due to
acute respiratory distress, and the last died 187 days
post-MRI due to VT. All deaths were reviewed and
adjudicated by the clinical events committee, and
none were considered to be related to the MR-ICD
system or MRI procedure.
VENTRICULAR LEAD PERFORMANCE. VPCT before
and post-MRI/waiting period are shown in the Central
Illustration. On average, the MRI group’s VPCT did not
change (0.00  0.16 V), whereas the control group
changed very little (0.02  0.16 V). There were
no signiﬁcant differences between the MRI and
control groups in the proportion of patients who met
the VPCT endpoint (100.0% MRI, 98.8% control;
p < 0.0001); thus, the pre-speciﬁed primary endpoint
for noninferiority was met. A total of 28 randomized
patients (21 [12%] MRI and 7 [8%] control subjects)
did not contribute data to the analysis, primarily due
to MRI examinations not being performed for various
reasons and death (Figure 2).
R-wave amplitudes before and post-MRI/waiting
period are shown in the Central Illustration. Mean
changes were small for both MRI (–0.10  2.67 mV) and
control (0.04  2.59 mV) subjects. There was no sig-
niﬁcant difference between the MRI and control
groups in the proportion of patients meeting the
R-wave amplitude endpoint (99.3% MRI, 98.8%
control; p¼0.0001) (Central Illustration); thus, the pre-
speciﬁed primary endpoint for noninferiority wasmet.
There were several other electrical properties
of the ICD systems that were included as sec-
ondary endpoints for this trial. Ventricular pacing
impedances from MRI/waiting period to 1-month
post-MRI/waiting period were stable in both the MRI
(468  83 ohms [U] vs. 464  83 U; p ¼ 0.12) and
control (475  97 U vs. 476  100 U; p ¼ 0.81) groups.
The proportion of MRI and control patients who
demonstrated deﬁbrillation impedances within the
standard ranges was also very similar. The right
ventricular deﬁbrillation impedance between 20 and
100 U was observed in 100% of MRI subjects and
98.8% of control subjects, (p < 0.0001 for non-
inferiority). The superior vena cava deﬁbrillation
impedance between 20 and 100 U at 1-month post
MRI/waiting period visit was 100% in both groups.
CENTRAL ILLUSTRATION Full-Body MRI Scanning in Patients With Implantable Cardioverter-Deﬁbrillators
Gold, M.R. et al. J Am Coll Cardiol. 2015; 65(24):2581–8.
(Top) Ventricular pacing capture threshold changes from the pre-magnetic resonance imaging (MRI) visit to the 1-month post-MRI visit.
The data to the right of the vertical dashed line represents the percentage of patients with a >0.5 V increase in ventricular pacing capture
threshold, which was the pre-speciﬁed endpoint to be tested. (Bottom) Ventricular sensing amplitude changes from the pre-MRI visit to the
1-month post-MRI visit. Points above the line labeled success/failure (a 25% decrease from 0 to 4 mV pre-MRI/waiting, and a 50% decrease
for $4 mV) represent successful subjects. The other line is the line of unity.
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2586A total of 34 episodes of VT/VF occurred after MRI
in 24 subjects. Of those, 20 were induced on the basis
of protocol requirements and 14 were spontaneous
events. None (0.0%) were noted to have a signiﬁcant
detection delay. The longest observed detectiondelay due to undersensing was 0.19 s, which is an
expected occurrence in any ICD.
ATRIAL LEAD PERFORMANCE. There were 120 pa-
tients implanted with a dual-chamber ICD. At the
1-month post-MRI/waiting period visit, there were
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control patients evaluated who demonstrated
a #0.5 V increase in atrial pacing capture threshold at
0.4 ms (98.7% MRI, 100% control subjects; non-
inferiority p ¼ 0.006), with mean changes of 0.01 
0.18 V and0.020.13 V, respectively. The proportion
of patients who demonstrated a #50% decrease in
P-wave amplitude was very similar between groups
(97.4% MRI, 97.1% control; non-inferiority p ¼ 0.005).
Atrial pacing impedances from MRI/waiting period to
1-month post-MRI/waiting period were stable in both
theMRI (481 62U vs. 483 60U; p¼0.71) and control
(486  50 U vs. 489  49 U; p ¼ 0.63) groups and with
minimal differences observed.
DISCUSSION
This is the ﬁrst randomized trial in humans of the
safety and efﬁcacy of full-body MRI on an ICD
system that was designed speciﬁcally for this pur-
pose. The primary ﬁnding was that no adverse effects
were noted with a standardized, comprehensive MRI
protocol. Moreover, pacing and sensing were not
signiﬁcantly affected by MRI, with normal arrhythmia
detection and deﬁbrillation function documented
following these examinations (Central Illustration).
These ﬁndings support the pre-clinical studies (12),
which indicated that the modiﬁcations made in this
system allow for safe MRI at 1.5-T when used in the
prescribed manner.
Although adverse effects of MRI on conventional
pacemaker and ICD systems are well documented
(14–16), the magnitude of this problem with
contemporary devices has been questioned in some
studies. Speciﬁcally, several single-center trials have
shown that such imaging can be performed safely in
certain situations (17,18). Although adverse events
are low in these reports, these studies typically
restricted scans to nonthoracic regions, excluded
pacemaker-dependent patients, and included a small
proportion of ICD patients compared with pacemaker
patients (19). By including a wide variety of cardio-
vascular implantable electronic device system com-
ponents, imaging techniques, and patient positions
in these studies, an evaluation of safety is difﬁcult to
assess.
MRI scans have been restricted to outside of the
thoracic region to decrease the risk of lead electrode
tip heating (20). Moreover, these previous studies
were performed in selective patients at highly-
experienced centers. We now show that the modiﬁ-
cations of the ICD system employed in this trial allow
for safe 1.5-T MRI with <2.0 W/kg speciﬁc absorption
rate and with no restrictions on scan location, heartrate, rhythm, or pacemaker dependency. Impor-
tantly, this study was performed in a large number of
centers in diverse geographies with highly-variable
scanning experience.
There have been several concerns regarding the
risks of MRI among ICD patients (12). These include
the induction of ventricular arrhythmias during the
MRI procedure, adverse changes in pacing or sensing
as a consequence of MRI, and abnormal deﬁbrillation
function. No patient in this study had a ventricular
arrhythmia during the MRI procedure. Moreover,
pacing and sensing function were stable, with mini-
mal changes documented in the 1-month period
following MRI and no signiﬁcant difference com-
pared with a nonimaged control group. One of the
theoretical effects of MRI on ICDs is the possible
interference with tachyarrhythmia detection. To our
knowledge, this is the ﬁrst prospective study to eval-
uate sensing and detection following MRI. These in-
clude both spontaneous and induced VT/VF episodes
in a subset of patients. We found no effect on sensing
of VT/VF and therapy delivery, with only a minimal
delay to detection, which is within normal limits.
The use of a dedicated mode (SureScan) during ICD
imaging facilitates programming of the device into a
compatible state for the MRI procedure. Asynchro-
nous pacing is available to support pacing-dependent
patients. SureScan disables tachyarrhythmia sensing
and deﬁbrillation therapies. However, accidental
permanent deactivation of devices for elective
procedures has been associated with patient deaths
(21). Thus, to mitigate this safety risk, an obligatory
6-h timeout of these settings ensures that inadvertent
long-term inactivation of ICD therapy is avoided.
The SureScan settings are stored in nonvolatile
device memory to maintain these settings during
an electrical reset. Finally, ﬁlters were added to the
telemetry circuitry to reduce the likelihood of device
damage caused by MRI. These design changes con-
tribute to patient safety and proper device operation
during MRI, compared with conventional ICDs.
STUDY LIMITATIONS. This study should be inter-
preted with certain methodological limitations. Only
a single MRI system and 2 DF4 lead models of limited
lengths were tested on 1.5-T MRI machines, so these
ﬁndings should not be extrapolated to other systems,
leads, or lead lengths; nonpectoral implantation sites;
or 3T scanners until further research is completed.
Scans were performed a period of time after implant,
and therefore, scanning prior to the lead maturation
period was not assessed. The follow-up was short as
it was designed to assess the early effect of MRI on
ICD function. Therefore, the long-term effect on ICD
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Although diagnostic MRI can be performed safely
in some patients with ICDs, it is usually contra-
indicated because of the risk of causing device
malfunction. In a randomized clinical trial,
patients with an ICD speciﬁcally designed for
compatibility safely tolerated MRI even when
pacemaker-dependent und undergoing whole-body
MRI scans.
TRANSLATIONAL OUTLOOK: Larger studies are
needed to ensure that low incidence complications,
such as sustained ventricular arrhythmias or pertur-
bations of deﬁbrillation energy thresholds, can be
reliably avoided when patients with this type of ICD
are subjected to high-intensity MRI.
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2588function cannot be determined, although observa-
tional clinical trials do not indicate a delayed effect of
MRI on device function. Finally, the study restricted
patients with de novo implants, so safety with more
chronic leads was not assessed.
CONCLUSIONS
This is the ﬁrst-in-human randomized study of an ICD
system designed for full-body MRI at 1.5-T. The data
support that the system is safe with MRI examina-
tions, showing no evidence of any adverse effect on
the electrical performance or the ability to treat
ventricular arrhythmias.
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